Vertex Ventures HC
39
68M
27
3.90
1
0.31
4
- Stages of investment
- Areas of investment
Summary
The fund was located in North America if to be more exact in United States. The leading representative office of defined VC is situated in the Palo Alto.
Deals in the range of 10 - 50 millions dollars are the general things for fund. This Vertex Ventures HC works on 15 percentage points less the average amount of lead investments comparing to the other organizations. Considering the real fund results, this VC is 15 percentage points less often commits exit comparing to other organizations. The average startup value when the investment from Vertex Ventures HC is 50-100 millions dollars. The high activity for fund was in 2017. The top amount of exits for fund were in 2019. The fund is constantly included in 2-6 investment rounds annually.
Among the various public portfolio startups of the fund, we may underline Earlens Corporation, Obsidian Therapeutics, Twentyeight-Seven Therapeutics The fund has exact preference in a number of founders of portfolio startups. In case when startup counts 1 or 5+ of the founder, the chance for it to get the investment is meager. Among the most popular fund investment industries, there are Health Care, Health Diagnostics. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.
The overall number of key employees were 2.
The typical case for the fund is to invest in rounds with 8-9 participants. Despite the Vertex Ventures HC, startups are often financed by Vertex Ventures, New Enterprise Associates, Versant Ventures. The meaningful sponsors for the fund in investment in the same round are Morgenthaler Ventures, Windham Venture Partners, Versant Ventures. In the next rounds fund is usually obtained by Vertex Ventures, Windham Venture Partners, New Enterprise Associates.
Investments analytics
Analytics
- Total investments
- 39
- Lead investments
- 1
- Exits
- 4
- Rounds per year
- 3.90
- Follow on index
- 0.31
- Investments by industry
- Biotechnology (29)
- Health Care (25)
- Medical Device (13)
- Therapeutics (12)
- Medical (10) Show 13 more
- Investments by region
-
- United States (36)
- United Kingdom (1)
- Switzerland (1)
- China (1)
- Peak activity year
- 2017
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 10
- Avg. valuation at time of investment
- 27M
- Group Appearance index
- 1.00
- Avg. company exit year
- 14
- Avg. multiplicator
- 2.61
- Strategy success index
- 0.30
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Bicycle Therapeutics | 01 Jun 2017 | Biotechnology, Medical Device, Therapeutics | Early Stage Venture | 52M | England, Cambridge, United Kingdom |
| TORL BioTherapeutics | 10 Apr 2024 | Biotechnology, Biopharma, Clinical Trials | Early Stage Venture | 158M | United States, California, Los Angeles |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.